Overview
- Analyses presented at the European Congress on Obesity used Danish health registries to track people who started semaglutide between 2022 and 2024.
- Among women with recent migraine treatment, triptan use fell by about 7% to 8% over the first year after starting semaglutide, with no significant change in men.
- Younger women saw the largest drop in migraine medicines, as those aged 18 to 35 cut triptan use by 18%.
- In a separate nationwide cohort of 27,523 people with asthma and overweight or type 2 diabetes, GLP-1 use was associated with 26% fewer exacerbations and 14% less reliever inhaler use.
- Investigators said weight loss likely drives much of the effect, the migraine study was sponsored by Novo Nordisk, and proposed anti-inflammatory or brain pathway actions remain unproven.